Relationship of homocysteine to markers of platelet and endothelial activation in 'high risk' hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial
Relationship of homocysteine to markers of platelet and endothelial activation in 'high risk' hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial
复制标题
DOI:
10.1016/j.ijcard.2003.06.002
复制
发表时间:
2004-04-01
影响因子:
3.5
通讯作者:
Lip, GYH
中科院分区:
文献类型:
--
作者:
Spencer, CGC;Martin, SC;Lip, GYH
Objective: To examine the relationship between plasma homocysteine (HCY) and theological, endothelial and platelet markers in 'high risk' hypertensive patients. Design: Cross-sectional study. Subjects and Methods: A total of 165 consecutive hypertensive patients (136 male; mean age 63 years (S.D. 8)) at high risk of cardiovascular disease who screened for inclusion in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) were studied along with 38 population normotensive healthy controls. We measured levels of plasma homocysteine [high pressure liquid chromatography (HPLC)], soluble P-selectin, a marker of platelet function, von Willebrand factor (vWF), an index of endothelial damage/dysfunction [both by ELISA] and fibrinogen (CLAUSS). The Framingham cardiovascular and cerebrovascular risk scores were calculated. Results: Hypertensives had significantly higher blood pressure (BP) [165/90(16/10) vs. 138/82(12/8) mm Hg, p < 0.0001], sP-sel [54(44-67) vs. 45(35-57) ng/ml, p = 0.002], vWF [133(34) vs. 110(28) IU/dl, p < 0.0001], and fibrinogen [2.98(2.523.47) vs. 2.43(2.20-2.83)g/l, p=